Background: The SPRINT trial showed a beneficial effect of systolic blood pressure treatment targets of 120 mmHg on cardiovascular risk compared to targets of 140 mmHg. However, differences in medication use, most importantly diuretics, are suggested as an alternative explanation. This post-hoc analysis aimed to determine whether the reduced event rate can be attributed to changes in systolic blood pressure (ÁSBP). Methods: Analyses were based on all 9361 participants of the SPRINT trial. ÁSBP was defined as the change between baseline and 6-month follow-up systolic blood pressure. Major cardiovascular events were myocardial infarction, other acute coronary syndromes, stroke, heart failure, or cardiovascular death. Cox regression was used to describe the relation between ÁSBP and major cardiovascular events. Analyses were performed separately for patients in the lowest tertile of baseline systolic blood pressure, as the SPRINT trial reported the highest treatment effect in this subgroup. Results: The relation between ÁSBP and major cardiovascular events was a hazard ratio per 10 mmHg decrease of 0.93 (95% confidence interval 0.89-0.98). Similar results were found within the lowest tertile of baseline systolic blood pressure: hazard ratio per 10 mmHg decrease 0.91 (95% confidence interval 0.82-1.01). Conclusion: Our results show that lowering blood pressure prevents cardiovascular disease. However, not all the positive effects in the SPRINT trial could be explained by ÁSBP. Alternative explanations, such as differences in medication use, should be considered for the positive findings of the SPRINT trial.
Introduction
Blood-pressure lowering is an essential component of cardiovascular disease (CVD) prevention. 1 However, blood-pressure treatment targets are still debated. The SPRINT trial investigated the effect of intensive lowering of systolic blood pressure (SBP) to less than 120 mmHg (intensive treatment) versus less than 140 mmHg (standard treatment) on a composite outcome of major cardiovascular events (MCVEs), defined as myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes. 2 The results suggest that intensive treatment is beneficial (hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.64-0.89), even in high-risk and elderly populations, and in patients with manifest vascular disease. The effect was most prominent in patients within the lowest tertile of baseline SBP (<132 mmHg, HR 0.70, 95% CI 0.51-0.95). However, differences in medication use, most importantly diuretics, are suggested as an alternative explanation of the SPRINT trial results. This post-hoc analysis aimed to determine whether the benefit observed in the SPRINT trial can be attributed to changes in SBP (ÁSBP). We thus quantified the relation between ÁSBP and MCVEs. 
Methods
Analyses were based on all 9361 SPRINT trial participants, enrolled between November 2010 and March 2013. During a median follow-up of 3.2 (interquartile range 2.7-3.8) years, 562 events were observed. SBP was the mean of three unattended measures after 5 minutes of seated rest in a quiet room. ÁSBP was defined as the change between baseline and 6-month follow-up SBP. Importantly, baseline blood pressure was not used for screening, thus was not sensitive to regression to the mean effects. If 6-month SBP was missing, the last observation was carried forward. MCVEs were obtained with structured interviews every 3 months for self-reported CVD. Medical records were obtained for documentation of events. Cox regression was used to describe the relation between ÁSBP and MCVEs. Ten-year CVD risk, based on the Framingham risk score, was included as a possible confounder. The presence of non-linearity was tested using an analysis of variance (ANOVA) of the model with and without a quadratic term for ÁSBP. Non-linearity was assumed at P < 0.05. Interaction between ÁSBP and tertiles of baseline SBP was tested with an ANOVA.
Results
In all patients, the relation between ÁSBP and MCVEs was linear (P-value 0.07) with a HR per 10 mmHg decrease of 0.93 (95% CI 0.89-0.98; Figure 1(a) ). No interaction was found between ÁSBP and tertiles of baseline SBP (P-value 0.88). However, as the SPRINT trial reported the highest treatment effect for patients in the lowest tertile of baseline SBP (<132 mmHg) and was not powered to detect interaction, the results are presented separately for this subgroup. In patients within the lowest tertile, the relation between ÁSBP and MCVEs was linear (P-value for non-linearity of 0.13) with a HR per 10 mmHg decrease of 0.91 (95% CI 0.82-1.01; Figure 1(b) ).
Discussion
This post-hoc analysis of the SPRINT trial showed that lowering blood pressure prevents CVD. However, our results suggest that the positive result of this trial is not fully explained by ÁSBP. The mean observed ontreatment ÁSBP between both arms of the SPRINT trial was 12 mmHg, which corresponds to a HR of 0.92 (95% CI 0.87-0.97) according to our findings. The observed HR in the trial, however, was 0.75 (95% CI 0.64-0.89). Similarly, for patients with a baseline SBP less than 132 mmHg, the mean observed on-treatment ÁSBP between both arms was 12 mmHg, which corresponds to a HR of 0.90 (95% CI 0.79-1.01). The observed HR in this subgroup, however, was 0.70 (95% CI 0.51-0.95). Therefore, alternative explanations for the positive findings of the SPRINT trial should be considered. One possible explanation may be derived from differences in therapy strategies, as there was 67% diuretic use in the intensive treatment arm and 43% in the standard treatment arm. Low-dose diuretics are known to be the most effective treatment for preventing CVD, 3 in particular heart failure, which contributed most to the primary outcome in the SPRINT trial.
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